超级碰在线-超级碰碰永久免费视频播放-超级碰碰碰免费视频播放-超级碰碰碰免费视频-亚洲国产99在线精品一区69堂-亚洲高清资源在线观看

美國Response Genetics,Inc. (RGI)
美國Response Genetics, Inc. ("RGI")反應遺傳學公司（“RGI”）成立于1999年，其總部設美國加利福尼亞州洛杉磯.
是從事研究和其專利及專利技術為基礎的藥物基因癌癥診斷測試的發展。RRGI的技術使提取和從腫瘤標本提取基因的遺傳信息分析，存儲為福爾馬林固定石蠟包埋標本。 RGI的產生，目前主要是在其專有的分析標本的臨床試驗藥物基因測試服務，銷售到制藥行業的收入。

Response Genetics, Inc. ("RGI") is engaged in the research and development of pharmacogenomic cancer diagnostic tests based on its proprietary and patented technologies. RGI''s technologies enable extraction and analysis of genetic information from genes derived from tumor samples stored as formalin-fixed and paraffin embedded specimens. RGI currently generates revenue primarily from the sales of its proprietary analytical pharmacogenomic testing services of clinical trial specimens to the pharmaceutical industry. The company was founded in 1999 and its principal headquarters are located in Los Angeles, California.

Response Genetics,Inc. (RGI) was founded in 1999 to leverage breakthrough, patented technology from USC for the “extraction of genetic information from formalin-fixed, paraffin-embedded clinical trial samples.” Until that time, RNA was only available from fresh frozen specimens; it was not possible to extract meaningful genetic information from diagnostic specimens fixed and stored in paraffin before the discovery of RGI's patented method.

Our success in developing this technology allows us to deliver tangible benefits to pharmaceutical companies and to create new platforms to support the industry with more efficient, cost-effective analysis of clinical trial samples, leading to the development of more “personalized” patient therapies.

Executive Management
Kathleen Danenberg, President and CEO
Kathy Danenberg has been the Chief Executive Officer for Response Genetics, Inc. since 2002. With her vision and leadership the Company has become a leading provider of molecular analysis services for some of the world's leading pharmaceutical companies.

Ms. Danenberg's began her career in molecular research and developed broad expertise in a variety of areas and applications. While at USC, Ms. Danenberg invented a breakthrough patented method to extract RNA from formalin-fixed paraffin embedded tissue specimens which became the basis for the establishment of Response Genetics, Inc. , Ms. Danenberg's research on the kinetic mechanism of thymidylate synthase provided the rationale for use of the 5-FU-leucovorin combination in colorectal cancer. She designed and carried out experiments demonstrating that 5-FU could alter RNA splicing and developed methods for using the polymerase chain reaction to quantitatively measure gene expression levels in tumor tissues.

Prior to her work at USC, Ms. Danenberg worked with the renowned enzyme kineticist Dr. W.W. Cleland at the University of Wisconsin to elucidate the mechanism of action of the enzyme hexokinase. Ms Danenberg has a world-wide reputation in the field of pharmaco genomics and is a frequent lecturer on a variety of subjects in this field. Ms. Danenberg has published over 70 peer-reviewed articles and is an invited lecturer for various scientific meetings both nationally and internationally in the field of pharmacogenomics. She received a B.S. in Biochemistry from the University of Wisconsin.

Tom Stankovich, CFO
Thomas Stankovich joined us as our Vice President, Chief Financial Officer and Secretary in December 2006. Mr. Stankovich has gained financial and business experience over the past 20 years working in both domestic and international operations with publicly-traded companies in the pharmaceutical and biotechnology industries.

Mr. Stankovich most recently was Executive Vice President and Chief Financial officer at Cobalis Corp. from December 2005 to December 2006. Prior to his position at Cobalis Corp., he worked at MP Biomedicals, LLC where he served as Senior Vice President and Chief Financial Officer from July 2003 to December 2005. He served as Senior Vice President and Chief Financial Officer for Ribapharm, Inc. from December 2001 to January 2003 (now part of Valeant Pharmaceuticals International) where he helped complete an initial public offering in April 2002.

Since 1986, Mr. Stankovich has served in various executive financial management positions for ICN Pharmaceuticals, Inc. (now renamed Valeant Pharmaceuticals International) including Vice President, Chief Financial Officer for ICN International A.G., and Vice President and Controller for ICN Europe. Mr. Stankovich holds Bachelor of Science degrees in both accounting and finance from California State University, Northridge.

Denise McNairn, Vice President, General Counsel
Denise McNairn joined Response Genetics as our Vice President and General Counsel in February 2007. Prior to joining the business, from 2001 to 2007, Ms. McNairn was an attorney at Kenyon & Kenyon LLP. Her legal experience covers all areas of intellectual property, including patent and trademark litigation, patent prosecution, and licensing. Ms. McNairn's patent litigation experience is focused in the life sciences, including pharmaceuticals, biotechnology and devices.

Prior to Kenyon & Kenyon, Ms. McNairn worked as a Technology Transfer Specialist at the National Cancer Institute Technology Transfer Branch, where she began her career in drafting and negotiating transactional agreements. Prior to beginning her legal career, Ms. McNairn worked a number of years in the biotechnology field and was an infectious disease researcher.

Ms. McNairn received her B.S. from Virginia Polytechnic Institute and State University, an M.S. from Johns Hopkins University and her J.D. from the University of Maryland School of Law.

Company Management
Eric Alcorn, Vice President, Finance and Administration
Mr. Alcorn joined Response Genetics in March, 2000 as Vice President, Finance. He served as Executive Vice President and Treasurer of USC Surgeons, Inc. and as Vice Chairman, Financial Affairs for the USC Department of Surgery since 1990.

Prior to this he served for 10 years in various corporate and hospital management positions with publicly held National Medical Enterprises. Mr. Alcorn received a Masters in Health Services Administration from the University of Southern California and a B.A. in Biology and Chemistry from Whittier College, Los Angeles.

Janine Cooc, Vice President, Regulatory Affairs
Ms. Cooc has been the Director of Regulatory Affairs for Response Genetics since 2005. Ms. Cooc joined Response Genetics in 2001 and held positions in both research and operations, including as Head of Operations, North America. Prior to this she gained extensive experience in clinical diagnostics and clinical development equirements while holding various laboratory positions with publicly held companies, including Quest Diagnostics Inc. Prior to Quest Diagnostics, Ms. Cooc held research and clinical diagnostics positions at SmithKline Beechem Clinical Laboratory and Loyola Marymount University.

Ms. Cooc received a Masters in Regulatory Science from the University of Southern California and a B.S. in Biochemistry from Loyola Marymount University.